Please use this identifier to cite or link to this item: https://repository.monashhealth.org/monashhealthjspui/handle/1/36761
Conference/Presentation Title: New strategy to restore erectile function after radical prostatectomy novel minimally invasive end-toside sural nerve grafting procedure.
Authors: Coombs C.;Reece J.;Dangerfield D.
Institution: (Dangerfield) Complete Urology Care, Brighton, Australia (Dangerfield) Monash Medical Centre, Clayton, Australia (Coombs) University of Melbourne, Parkvilla, Australia (Reece) University of Melbourne Centre for Cancer Research, Parkvilla, Australia
Presentation/Conference Date: 6-May-2019
Copyright year: 2019
Publisher: Blackwell Publishing Ltd
Publication information: BJU International. Conference: 2019 Annual Scientific Meeting of the Urological Society of Australia and New Zealand. Brisbane, QLD Australia. 123 (Supplement 2) (pp 39), 2019. Date of Publication: April 2019.
Abstract: Introduction and Objectives: We assessed the potential of innovative nerve grafting surgery to restore erectile function, and improve sexual QoL in men with erectile dysfunction after nerve-, and nonnerve- sparing radical prostatectomy. Method(s): In a retrospective chart review, medical records were abstracted for men who had novel penile reinnervation surgery between 5th March 2015, and May 18th 2017, were < 70 years, and had low comorbidity burden. Novel surgery involved bilateral end-to-side somatic-toautonomic sural nerve grafts from the femoral nerve to the penile corpora cavernosa, with a judicious partial fascicular neurotomy of the femoral nerve. Erectile function, and sexual QoL outcomes were serially assessed using the International Index of Erectile Function (IIEF-5), and sexual domain of the Expanded Prostate Cancer Index Composite (EPIC-26), respectively. The proportion, and corresponding 95% confidence intervals of men with clinically significant outcomes after nerve grafting compared with prior to nerve grafting were determined. Result(s): Prior to nerve grafting surgery, all patients were impotent following their radical prostatectomy. The median age of men at nerve grafting was 64 years (range, 49- 69). The median time between nerve-, and non-nerve-sparing radical prostatectomy, and novel nerve grafting surgery was 2.4 years (range, 1.8-4.3 years), and 2.2 years (range, 0.3-12.9), respectively. Median follow-up was 18 months (range, 12-36). At 12 months post-nerve grafting, 71% (95% CI 44% to 90%) of patients had erectile function recovery sufficient for satisfactory sexual intercourse. In men with restored erectile function, 100% (95% CI 74% to 100%), and 83% (95% CI 52% to 98%) had clinically significant improvements in sexual function, and reduced bother, respectively. Table 3 Proportions of clinically relevant outcomes at 12 months post-nerve grafting compared with pre-nerve grafting. aProportions, and corresponding 95% confidence intervals were calculated using the exact method of Clopper and Pearson.30 (Table presented) Conclusion(s): Innovative minimally invasive end-to-side sural nerve grafting has the potential can restore erectile function, and improve sexual QoL in men with erectile dysfunction following nerve-, or non-nerve-sparing radical prostatectomy.
Conference Start Date: 2019-04-13
Conference End Date: 2019-04-16
DOI: http://monash.idm.oclc.org/login?url=http://dx.doi.org/10.1111/bju.14724
ISSN: 1464-410X
URI: https://repository.monashhealth.org/monashhealthjspui/handle/1/36761
Type: Conference Abstract
Appears in Collections:Conferences

Show full item record

Google ScholarTM

Check


Items in Monash Health Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.